Blackstone Life Sciences VI raised $6.3 billion, showing strong investor demand. But recent health care funds lagged broader private equity, and tougher deal searches and proposed ownership limits leave no clear change to Blackstone's outlook.
That raise shows investors still committed substantial money to Blackstone's health care investing arm. But recent health care fund returns trailed broader private equity, and larger funds may have fewer suitable businesses to buy. A proposed ownership bill adds another concern, so the story gives mixed signs rather than a clear change to Blackstone's outlook.
JPMorgan appears only in unrelated link text. The article gives no new information about its business, so this story does not change its outlook.
Follow Blackstone (BX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BX